Division of Anti-Infective Products, Food and Drug Administration, Silver Spring, Maryland.
Clin Infect Dis. 2014 Feb;58(4):537-9. doi: 10.1093/cid/cit719. Epub 2013 Oct 30.
We report hypersensitivity reactions associated with fidaxomicin, an antibacterial drug approved for the treatment of Clostridium difficile-associated diarrhea. These reactions are viewed as significant because of severity and unexpected because fidaxomicin is minimally absorbed. The fidaxomicin labeling was revised to include information about the possibility of hypersensitivity reactions.
我们报告了与非达霉素相关的过敏反应，非达霉素是一种批准用于治疗艰难梭菌相关性腹泻的抗菌药物。这些反应被认为是严重的，而且是意料之外的，因为非达霉素的吸收很少。非达霉素的标签已被修订，以包括关于过敏反应可能性的信息。
